Medtronic PLC (NYSE:MDT) Receives $110.44 Average Target Price from Analysts

Medtronic PLC (NYSE:MDT) has received a consensus rating of “Moderate Buy” from the twenty-six research firms that are covering the stock, Marketbeat Ratings reports. Twelve equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $110.1111.

MDT has been the subject of a number of recent research reports. Cowen reiterated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Jefferies Financial Group restated a “hold” rating and set a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medtronic in a report on Monday. Wells Fargo & Company increased their price target on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Finally, Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Corundum Trust Company INC purchased a new position in Medtronic during the third quarter worth approximately $27,000. 1248 Management LLC purchased a new stake in shares of Medtronic during the 1st quarter valued at $26,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the 3rd quarter worth $29,000. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic in the 2nd quarter worth $27,000. Finally, Imprint Wealth LLC acquired a new position in Medtronic in the third quarter valued at $31,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Performance

NYSE MDT opened at $97.77 on Friday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic has a fifty-two week low of $79.29 and a fifty-two week high of $106.33. The business has a fifty day moving average of $97.26 and a 200-day moving average of $93.18. The stock has a market cap of $125.34 billion, a price-to-earnings ratio of 26.35, a price-to-earnings-growth ratio of 2.60 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter last year, the business posted $1.26 EPS. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts predict that Medtronic will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s payout ratio is 76.55%.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.